Kumar · Neuromolecular medicine 2026 · Comparative animal study · n=?

Enhanced Neurophysiological Benefits of Magnesium-Acetyl-Taurate Over Magnesium-L-Threonate: A Comparative pre-clinical Study on Bioavailability, Synaptic Plasticity and Cognitive Functions.

Cited 3 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Pre-clinical animal research in rats

PubMed 42084749 · doi:10.1007/s12017-026-08929-6 · record verified 2026-08-31

What was done

Adult Wistar rats were treated with magnesium-L-threonate (MLT at 115 mg/kg or 450 mg/kg), magnesium-acetyl-taurate (MAT at 150 mg/kg or 500 mg/kg), or combined MLT and MAT therapy. The primary endpoint was tissue Mg²⁺ concentration across blood plasma, cerebrospinal fluid (CSF), muscle, and brain tissues. Secondary endpoints included behavioral assays (spatial learning, memory, anxiety, motor coordination, neuromuscular strength), biochemical markers of oxidative stress (SOD, GSH, catalase, CoQ10), mitochondrial electron transport chain complexes, neurotransmitters (dopamine, GABA, glutamate), molecular markers of synaptic plasticity (BDNF, CREB, synaptophysin, PSD-95, Nrf2, HO-1, cAMP), and histological assessment of myelination.

What was found

The abstract reports no numerical values, effect sizes, or confidence intervals for any measured outcome. Descriptively, MAT resulted in higher Mg²⁺ levels in biological samples and produced greater improvements in cognitive performance, motor coordination, and neuromuscular strength compared to MLT. MAT and combined therapy were reported to significantly improve spatial learning, memory, anxiety behaviors, antioxidant enzymes, mitochondrial complex expression, and synaptic protein levels, alongside improved neuronal myelination and structural integrity.

Why it matters

Magnesium-L-threonate is widely studied for brain bioavailability, but these findings suggest magnesium-acetyl-taurate may offer superior central nervous system penetration and broader neuroprotective effects in preclinical models.

Limits

The abstract provides no quantitative data, sample size (n), or statistical values to evaluate the magnitude or precision of the effects. As an animal study in healthy adult rats, the findings cannot be directly translated to human pharmacokinetics, clinical cognitive decline, or neurological disease without human clinical trials.

Cited by